A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)

Phase 1/2 Recruiting 9 enrolled Hillhurst Biopharmaceuticals, Inc. National Heart, Lung, and Blood Institute (NHLBI) · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a multi-center, open label Phase 2a clinical trial in subjects with sickle cell disease to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of HBI-002, an orally administered liquid containing carbon monoxide (CO), with doses daily for 14 days.

Timeline

Start: 2025-02-15
Primary completion: 2026-03-31
Completion: 2026-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HBI-002	Unknown	—	Oral

A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)

Summary

Timeline

Drugs

Indications